Drug Trial Radar · NCT06350123
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
324
Actual
Start
May 1, 2024
Primary completion
May 9, 2025
Study completion May 9, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy, safety and tolerability of balcinrenone/dapagliflozin compared with dapagliflozin alone on patients with chronic kidney disease (CKD) and albuminuria. This study will evaluate the effect of the balcinrenone/dapagliflozin on urinary albumin-to-creatinine ratio (UACR), compared with dapagliflozin in patients with CKD. This is a dose-finding study aiming to identify an optimal dose of balcinrenone/dapagliflozin for a future Phase III study in patients with CKD.
Conditions
- Chronic Kidney Disease
Interventions
Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug
1 capsule of balcinrenone/dapagliflozin 15 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mgDrug
1 capsule of balcinrenone/dapagliflozin 40 mg/10 mg and 1 tablet of matching placebo for dapagliflozin 10 mg once daily, oral use
Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozinDrug
1 tablet of dapagliflozin 10 mg and 1 capsule of matching placebo for balcinrenone/dapagliflozin once daily, oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relative Change in Urine Albumin-to-Creatinine Ratio (UACR) From Baseline to Week 12Time frame: Baseline (Day 1) until Week 12 (Day 85)
Locations
92 sites in 15 countries. Site status is shown where the registry gives one.
Research Site
Sheffield, Alabama
Research Site
Glendale, California
Research Site
Waterbury, Connecticut
Research Site
Hialeah, Florida
Research Site
Miami Lakes, Florida
Research Site
Annapolis, Maryland
Research Site
New Bern, North Carolina
Research Site
El Paso, Texas
Research Site
Houston, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Ogden, Utah
Research Site
Salt Lake City, Utah
Research Site
Salt Lake City, Utah
Research Site
Norfolk, Virginia
Research Site
Linz, Austria
Research Site
Sankt Pölten, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Vienna, Austria
Research Site
Wels, Austria
Research Site
Porto Alegre, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Burgas, Bulgaria
Research Site
Dobrich, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
London, Ontario, Canada
Research Site
Waterloo, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Changchun, China
Research Site
Changzhou, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.